Lichen striatus post-COVID–19 vaccination

Belina, Morgan E.; Sarver, Melissa M.; Al‐Rohil, Rami N.; Fresco, Amber

doi:10.1016/j.jdcr.2021.07.031

Cited by 12 publications

(12 citation statements)

References 6 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Histopathologic studies on lichenoid lesions reported dense and diffuse lymphocytes and plasma cells infiltration of the superficial and deep dermis. 51,68–74 Moreover, large neoplastic T lymphocytes among the lymphocytes population were noticed. 69 Furthermore, infiltrate extension to the dermoepidermal junction and scattered necrotic keratinocytes were detected in one sample.…”

Section: Resultsmentioning

confidence: 98%

A Systematic Review of Histopathologic Surveys on Mucocutaneous Biopsies in Patients Developed COVID-19 Vaccine-Related Dermatologic Manifestations

Salehi

Sadeghi

Kalantari

et al. 2022

The American Journal of Dermatopathology

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 98%

A Systematic Review of Histopathologic Surveys on Mucocutaneous Biopsies in Patients Developed COVID-19 Vaccine-Related Dermatologic Manifestations

Salehi

Sadeghi

Kalantari

et al. 2022

The American Journal of Dermatopathology

View full text Add to dashboard Cite

show abstract

“…Inverse lichen planus, oral lichen planus, generalized lichen planus, and relapses/flares of pre-existing lichen planus and lichen planopilaris have been reported with COVID-19 vaccines. [2][3][4][5] Recently, Belina et al 7 reported the case of a 42year-old woman with lichen striatus on her right arm that developed 3 days after the second dose of the Pfizer COVID-19 vaccine. The eruption appeared on her right wrist and spread proximally up her arm and right side of the chest.…”

Section: Discussionmentioning

confidence: 99%

Blaschkolinear acquired inflammatory skin eruption (blaschkitis) following COVID-19 vaccination

Rovira-López

Pujol

2022

JAAD Case Reports

View full text Add to dashboard Cite

“…Furthermore, hepatitis B and rabies vaccination were observed to be associated with pediatric LP [ 22 ]. Regarding COVID-19 vaccination, an associated onset of cutaneous LP was recently reported by Hiltun et al, Merhy et al, Piccolo et al, as well as Belina et al [ 23 , 24 , 25 , 26 ]. McMahon and co-workers found four cases with “lichen-like” histopathologic pattern among biopsies of 803 cutaneous reactions to COVID-19 vaccines [ 27 ].…”

Section: Introductionmentioning

confidence: 89%

Onset of Oral Lichenoid Lesions and Oral Lichen Planus Following COVID-19 Vaccination: A Retrospective Analysis of about 300,000 Vaccinated Patients

et al. 2022

View full text Add to dashboard Cite

Introduction: Onset of oral lichenoid lesions (OLL) or oral lichen planus (OLP) can be rare adverse reactions to vaccines. Recently, the first solitary cases were reported after COVID-19 vaccination. The aim of the present study was to assess if an increased frequency of OLL/OLP can be found after COVID-19 vaccination within a large real-world cohort. It was assumed that the incidence of OLL/OLP was significantly higher in subjects who received COVID-19 vaccine (cohort I) compared to individuals who were not vaccinated (cohort II). Patients and Methods: Initial cohorts of 274,481 vaccinated and 9,429,892 not vaccinated patients were retrieved from the TriNetX database (TriNetX, Cambridge, Massachusetts, USA), and matched for age, gender and the frequency of use of non-steroidal anti-inflammatory drugs, beta blockers, and angiotensin-converting enzyme inhibitors. Results: After matching each cohort, we accounted for 217,863 patients. Among cohort I, 146 individuals had developed OLL/OLP within 6 days after COVID-19 vaccination (88 and 58 subjects had received mRNA- and adenovirus vector-based vaccines), whereas in cohort II, 59 patients were newly diagnosed with OLL/OLP within 6 days after having visited the clinic for any other reason. The risk of developing OLL/OLP was calculated as 0.067% vs. 0.027%, for cohorts I and II, whereby the risk difference was highly significant (p < 0.001; log-rank test). RR and OR were 2.475 (95% CI = 1.829; 3.348) and 2.476 (95% CI = 1.830; 3.350), respectively. Discussion: The hypothesis was confirmed. Accordingly, the obtained results suggest that the onset of OLL/OLP is a rare adverse drug reaction to COVID-19 vaccines, especially to mRNA vaccines. Thus far, it remains unknown if specific components of the formulations cause a type IV hypersensitive reaction corresponding to OLL, or if the immune response post vaccination triggers a T cell-driven autoimmune reaction directed against the basal layer of keratinocytes of the oral mucosa in terms of OLP. Although OLL and OLP are both classified as premalignant lesions, spontaneous remission may be expected over time, at least in the case of OLL. Therefore, the presented findings should not place any limitation toward the use of COVID-19-vaccines in broad levels of the population.

show abstract

Lichen striatus post-COVID–19 vaccination

Cited by 12 publications

References 6 publications

A Systematic Review of Histopathologic Surveys on Mucocutaneous Biopsies in Patients Developed COVID-19 Vaccine-Related Dermatologic Manifestations

A Systematic Review of Histopathologic Surveys on Mucocutaneous Biopsies in Patients Developed COVID-19 Vaccine-Related Dermatologic Manifestations

Blaschkolinear acquired inflammatory skin eruption (blaschkitis) following COVID-19 vaccination

Onset of Oral Lichenoid Lesions and Oral Lichen Planus Following COVID-19 Vaccination: A Retrospective Analysis of about 300,000 Vaccinated Patients

Contact Info

Product

Resources

About